8-K: CRISPR Therapeutics Reports Q4 & FY25 Results, Advances Pipeline

CRISPR Therapeutics announced its fourth quarter and full year 2025 financial results, highlighting continued progress across its diverse gene-editing pipeline and global uptake of CASGEVY.

Summary

• Reported Q4 2025 revenue of $54 million and full year 2025 revenue of $116 million for CASGEVY.
• 64 patients received CASGEVY infusions in 2025, with 30 in Q4.
• 147 patients initiated the CASGEVY treatment process with first cell collection in 2025, nearly a three-fold increase from 2024.
• Cash, cash equivalents, and marketable securities stood at $1,975.8 million as of December 31, 2025.
• Net loss for Q4 2025 was $130.6 million, compared to $37.3 million for Q4 2024.
• Net loss for full year 2025 was $581.6 million, compared to $366.3 million for full year 2024.
• R&D expenses for Q4 2025 increased to $83.5 million from $71.7 million in Q4 2024, primarily due to licensing fees.
• Collaboration expense, net, significantly increased to $53.7 million in Q4 2025 from $10.4 million in Q4 2024, due to the absence of a comparable deferral in 2025.
• Positive pediatric data for CASGEVY in children ages 5-11 years with SCD or TDT were presented in December 2025, with global regulatory submissions expected in H1 2026.
• Advancing multiple in vivo liver editing programs (CTX310, CTX321, CTX460, CTX340) and siRNA-based programs (CTX611) in collaboration with Sirius Therapeutics.
• Zugocabtagene geleucel (zugo-cel) continues to advance in Phase 1 clinical trials for autoimmune diseases and Phase 1/2 for B-cell malignancies.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a mixed report. While clinical pipeline progress and CASGEVY's commercial uptake are strong positives, the significant widening of net loss and increased collaboration expenses raise financial concerns, indicating high costs associated with advanced R&D and commercialization efforts.

Positives

• CASGEVY generated $54 million in Q4 2025 revenue and $116 million for the full year 2025, reflecting continued growth in treated patients.
• Patient initiations and first cell collections for CASGEVY increased nearly three-fold in 2025 compared to 2024, with momentum continuing into 2026.
• CASGEVY access expanded, with approximately 90% of U.S. patients having reimbursed access and additional reimbursement secured in Scotland in January 2026.
• Positive pediatric data for CASGEVY (ages 5-11) were presented at ASH in December 2025, leading to expected global regulatory submissions in H1 2026.
• The FDA awarded a Commissioners National Priority Voucher for the pediatric CASGEVY submission, supporting expedited review.
• Cash, cash equivalents, and marketable securities increased to $1,975.8 million as of December 31, 2025, from $1,903.8 million in 2024.
• R&D expenses for the full year 2025 decreased to $284.8 million from $310.2 million in 2024.
• Continued progress across a broad and increasingly mature pipeline, including encouraging data from zugo-cel in autoimmune disease and oncology.
• Advancement of in vivo liver editing portfolio with CTX310 in Phase 1b, CTX321 in IND/CTA-enabling studies, and expected clinical trial initiations for CTX460 (mid-2026) and CTX340 (H1 2026).
• Progress in siRNA collaboration with Sirius Therapeutics, with CTX611 in Phase 2 and potential for a multi-billion-dollar market opportunity.
• Advancing CTX213, a deviceless beta cell replacement product candidate for Type 1 diabetes, towards the clinic with compelling preclinical efficacy.

Negatives

• Net loss significantly widened to $130.6 million for Q4 2025, compared to $37.3 million for Q4 2024.
• Full year 2025 net loss also widened significantly to $581.6 million, from $366.3 million in 2024.
• Collaboration revenue decreased to $0 for Q4 and full year 2025, compared to $35.0 million in the same periods of 2024.
• Total revenue decreased significantly to $0.864 million for Q4 2025 from $35.691 million in Q4 2024, and to $3.510 million for full year 2025 from $37.314 million in full year 2024.
• Collaboration expense, net, increased substantially to $53.7 million for Q4 2025 from $10.4 million for Q4 2024, and to $213.5 million for full year 2025 from $120.7 million for full year 2024, primarily due to the absence of a deferral in 2025 that was present in 2024.
• R&D expenses for Q4 2025 increased to $83.5 million from $71.7 million for Q4 2024, driven by licensing fees.

Risks

• Forward-looking statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied.
• Risks include those related to preclinical studies, clinical trials, pipeline products and programs (e.g., manufacturing capabilities, status of studies, potential expansion, data, safety, efficacy).
• Risks associated with the ability to use data from ongoing and planned clinical trials for the design and initiation of further clinical trials.
• Risks related to CRISPR Therapeutics' strategy, goals, anticipated financial performance, and the sufficiency of its cash resources.
• Risks concerning plans and expectations for the commercialization of CASGEVY, including anticipated patient access.
• Risks related to regulatory submissions and authorizations, including timelines for and expectations regarding regulatory agency decisions.
• Risks concerning the expected benefits of its collaborations.
• Risks related to the therapeutic value, development, and commercial potential of gene editing technologies and therapies, including CRISPR/Cas9 and SyNTase.

Future Outlook

Global regulatory submissions for CASGEVY in the pediatric age group (5-11 years) are expected to begin in the first half of 2026, with an expedited review supported by an FDA Commissioners National Priority Voucher. Updates on CTX310, CTX611, and zugo-cel clinical trials are expected in the second half of 2026. Clinical trial initiations for CTX460 and CTX340 are anticipated in mid-2026 and the first half of 2026, respectively. An update on the CTX321 Lp(a) program and the option to nominate additional siRNA targets are expected in 2026.

Management Comments

• "As we close out the fourth quarter, CRISPR Therapeutics continues to make steady progress across a broad and increasingly mature pipeline."
• "We made meaningful advances across multiple clinical and preclinical programs, including encouraging data from zugo-cel in autoimmune disease and oncology, continued global uptake of CASGEVY, and important developments across our in vivo liver editing portfolio, and momentum in our siRNA collaboration with Sirius Therapeutics."
• "At the same time, we continue to strengthen our platform capabilities to support long-term value creation. Together, these developments reflect continued execution across the portfolio."

Industry Context

StockSavvy.ai notes that CRISPR Therapeutics' continued expansion of CASGEVY's market access and pipeline advancements, particularly in in vivo gene editing and siRNA therapies, align with broader industry trends towards diversifying gene therapy applications beyond rare diseases and into larger markets like cardiovascular and autoimmune conditions. The significant increase in CASGEVY patient initiations demonstrates growing adoption for approved gene-editing treatments, setting a precedent for the emerging field. However, the substantial increase in net loss and collaboration expenses highlights the high R&D costs and complex financial structures inherent in pioneering biotechnology.

Stakeholder Impact

• Shareholders: Potential for long-term value creation through pipeline advancements and CASGEVY commercialization, but short-term financial losses may impact sentiment.
• Patients (SCD/TDT): Expanded access to CASGEVY and upcoming pediatric submissions offer new treatment options.
• Patients (Other diseases): Progress in diverse pipeline (liver editing, autoimmune, oncology, diabetes) offers future therapeutic potential.
• Employees: Continued execution across the portfolio and strengthening platform capabilities suggest stable operations and ongoing R&D efforts.
• Partners (Vertex, Sirius, Lilly): Ongoing collaborations indicate continued strategic alignment and shared development efforts.

Next Steps

• Global regulatory submissions for CASGEVY in pediatric age group (5-11 years) expected to begin in H1 2026.
• Update on CTX310 in Phase 1b clinical trials expected in H2 2026.
• Update on CTX321 Lp(a) program expected in 2026.
• Initiation of a clinical trial for CTX460 expected in mid-2026.
• Initiation of a clinical trial for CTX340 expected in H1 2026.
• CRISPR Therapeutics to lead global Phase 3 development of CTX611.
• Update on CTX611 (SRSD107) Phase 2 clinical trial expected in H2 2026.
• Update on the option to nominate up to two additional siRNA targets expected in 2026.
• Updates on zugo-cel Phase 1 clinical trials in autoimmune disease expected in H2 2026.
• Updates on zugo-cel Phase 1/2 clinical trial in B-cell malignancies expected in H2 2026.
• Additional updates on CTX213 (deviceless beta cell replacement) as development progresses.
• Presentations at Citi's 2026 Virtual Oncology Leadership Summit (Feb 18, 2026), TD Cowen 46th Annual Health Care Conference (March 2, 2026), and Leerink Partners Global Healthcare Conference (March 11, 2026).

Key Dates

Recommendation

While CRISPR Therapeutics demonstrates strong clinical and commercial progress with CASGEVY and a robust, diversified pipeline, the significant increase in net loss and collaboration expenses for the full year 2025 warrants caution. The company is in a high-growth, high-investment phase, and while future catalysts are promising, the current financial performance suggests a 'hold' position until there is clearer visibility on profitability or a more favorable risk-reward profile emerges from the extensive pipeline.

Keywords

CRISPR Therapeutics, CRSP, Gene Editing, CASGEVY, Exa-cel, Sickle Cell Disease, Beta Thalassemia, Autoimmune Disease, Immuno-Oncology, Liver Editing, siRNA, CTX310, CTX321, CTX340, CTX460, CTX611, Zugo-cel, CTX213, Financial Results, Biotechnology, Gene Therapy, Rare Diseases, Vertex Pharmaceuticals, Sirius Therapeutics